ArticleAmerican journal of cancer research2025
USP13 mediates resistance to Ibrutinib in diffuse large B-cell lymphoma via augmenting FHL1 stabilization.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoid malignancy in the world which is mainly divided to ABC type and GCB type. Ibrutinib benefits patients with ABC subtype DLBCL by inhibiting Bruton's tyrosine kinase (BTK), but there are still a lot of patients who are resistant to Ibrutinib. In this study, we found that post-translational modification played a regulatory role in mediating Ibrutinib resistance in DLBCL. The expression of USP13 was significantly higher in Ibrutinib-resistant U2932 cells compared with Ibrutinib-sensitive WSU-DLCL2 cells, and its expression was further increased both in WSU-DLCL2 and U2932 after exposure to Ibrutinib. USP13 overexpression significantly promoted cell growth and decreased Ibrutinib sensitivity in DLBCL while knockdown of USP13 significantly increased Ibrutinib-induced apoptosis and improved the sensitivity to Ibrutinib. Further studies showed that USP13 interacted with FHL1 and stabilized the expression of FHL1 via deubiquitination, thereby mediating the phosphorylation of ERK1/2, resulting in the decrease expression of Bax and the increase expression of Bcl-xL, thus mediating Ibrutinib resistance in DLBCL. The results of immunohistochemical staining of tumor tissue also indicated that the expression level of USP13 was negatively related to the prognosis of DLBCL patients. These new findings provided an experimental basis for overcoming Ibrutinib resistance in DLBCL and showed that USP13 is a potential therapeutic target and prognostic marker in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.